Three consecutive rises in Hytera Communications Corporation (002583.SZ): There is uncertainty in the progress of expanding into new markets.
Notice from Hytera (002583.SZ): The company's stock has been suspended for two consecutive trading days (September 20th and September 23rd)...
Hytera Communications Corporation (002583.SZ) announced that the closing price of the company's stock has deviated by more than 20% for two consecutive trading days (September 20th and September 23rd), indicating abnormal fluctuations in stock trading.
Regarding the recent expansion of the company's business in the Middle East, which investors are paying close attention to, the company reiterates the following: In recent years, the company has been continuously strengthening its business presence in emerging markets such as the Middle East, South Asia, Latin America, Africa, and countries along the "Belt and Road" initiative. In the first half of the year, facing business opportunities in the Middle East, the company has further expanded its market presence in the region and promoted overseas branding efforts to facilitate business expansion in the Middle East. The company also reminds investors that the progress of expanding into new markets is uncertain, and its impact on the company's performance is still to be observed.
Related Articles

Billion Industries Holdings Limited (02299) spent 39,200 Hong Kong dollars to repurchase 8,000 shares on April 10th.

Yue Yuen Industries (00551) total comprehensive operating income for the first three months decreased by 2.2% year-on-year to 1.985 billion US dollars.

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.
Billion Industries Holdings Limited (02299) spent 39,200 Hong Kong dollars to repurchase 8,000 shares on April 10th.

Yue Yuen Industries (00551) total comprehensive operating income for the first three months decreased by 2.2% year-on-year to 1.985 billion US dollars.

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.

RECOMMEND





